SCHEMBL492850

SCHEMBL492850

O=C(O)c1noc2cc([N+](=O)[O-])ccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.66
CYP1A2 P05177 1/20 0.66
HIF1A Q16665 1/20 0.50
ALDH1A1 P00352 5/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 3/20 0.45
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
IGFBP3 P17936 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833141 0.88 LMNA (0.52) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL29571343 0.88 LMNA (0.52) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL9037773 0.87 LMNA (0.64) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL17437900 0.84 LMNA (0.73) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL22424049 0.83 LMNA (0.75) LMNACYP1A2HIF1AALDH1A1MEN1
SCHEMBL28135759 0.83 LMNA (0.52) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL11790310 0.82 LMNA (0.60) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL11790831 0.80 CYP1A2 (0.57) LMNACYP1A2HIF1AALDH1A1TDP1
SCHEMBL492280 0.80 LMNA (0.63) LMNACYP1A2HIF1AALDH1A1MAPT
SCHEMBL11793171 0.80 LMNA (0.56) LMNACYP1A2HIF1AALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115976586-B Forward and reverse pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2025-03-14 CN claimed
CN-117418280-A Nickel spraying plating solution, preparation method and electroplating method 昆山一鼎工业科技有限公司 2024-01-19 CN claimed
CN-115976586-A Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2023-04-18 CN claimed
CN-115976586-B Forward and reverse pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2025-03-14 CN disclosed
CN-117418280-A Nickel spraying plating solution, preparation method and electroplating method 昆山一鼎工业科技有限公司 2024-01-19 CN disclosed
CN-115976586-A Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2023-04-18 CN disclosed
US-8273891-B2 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2012-09-25 US disclosed
US-8106066-B2 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2012-01-31 US disclosed
US-20100137288-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF SCHUMACHER RICHARD 2010-06-03 US disclosed
EP-2160352-A2 METHOD FOR THE PRODUCTION OF BINARY CLATHRATE HYDRATES OF HYDROGEN Arca, Simone (IT) 2010-03-10 EP disclosed
WO-2008142560-A2 METHOD FOR THE PRODUCTION OF BINARY CLATHRATE HYDRATES OF HYDROGEN ARCA SIMONE (IT) 2008-11-27 WO disclosed
EP-1940833-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2008-07-09 EP disclosed
US-20070078147-A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION 2007-04-05 US disclosed
WO-2007038367-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137288-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF CHRNA7, CHRNA5, CHRNA2 LMNA 2847/4885CYP1A2 1116/4885HIF1A 4598/4885
US-20070078147-A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof CHRNA7, CHRNA5, CHRNA2 LMNA 2847/4885CYP1A2 1116/4885HIF1A 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.